In today’s briefing:
- Taste Gourmet (8371 HK): Q3 FY24 Preview and Future Catalysts
- PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite
- Quiddity Leaderboard for Hang Seng Index Mar 24: More Room Being Created for IT Names?
- Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation
- Morning Views Asia: China Vanke , SJM Holdings
Taste Gourmet (8371 HK): Q3 FY24 Preview and Future Catalysts
- We expect Q3 FY24 revenues/profits to be >40%/>70% YoY for Taste Gourmet (8371 HK) for their results in early February.
- Another catalyst we look forward to in CY24 is the main board listing on HKex. The timeline, we believe, should be in the second half of the year.
- Trading at 6x PE with an 8.5% dividend yield and cash of 130 mn HKD, or about 21% of the market cap, is one of our top dividend gems.
PICC’s (1339 HK)’s Implied Stub Plumbs New Lows As Interest Rate Cuts Bite
- Back in October, I wrote in PICC’s (1339 HK) Lifetime Low Implied Stub that People’s Insurance (1339 HK) was trading at an all-time low implied stub. It’s widened further since.
- Over the past 12-months, excluding PICC’s 68.98% stake in PICC Property & Casualty (2328 HK), the market has assigned HK$42.6bn less for PICC’s steady and profitable life/health insurance stub ops.
- What gives? Falling interest rates is one. EV insurance in another. Yet this bifurcation is extreme.
Quiddity Leaderboard for Hang Seng Index Mar 24: More Room Being Created for IT Names?
- In this insight, we take a look at a group of names with reasonably high likelihood of being involved in index changes for the Hang Seng Index in March 2024.
- The index changes for the March 2024 index rebal will be announced on 16th February 2024.
- While the Hang Seng Index selection process is highly subjective, we continue to believe that identifying eligible names and grouping them by conviction level could be a valuable exercise.
Cloudbreak Pharma (拨康视云) Pre-IPO: Old Drug, New Formulation
- Cloudbreak Pharma, a China-based clinical-stage biotechnology company, plans to raise up to US$200m via a Hong Kong listing.
- In this note, we examine the company’s core products, namely CBT-001 and CBT-009, for pterygium and juvenile myopia respectively.
- We are seeing a lack of convincing sustainable innovation from the company. Pre-IPO investors and management are mediocre.
Morning Views Asia: China Vanke , SJM Holdings
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.